SPOTLIGHT: Boehringer beats Bayer drug to market

Boehringer Ingelheim won European approval for its new blood thinner Pradaxa to prevent clotting in patients after orthopedic surgery. The OK lets Pradaxa beat to market its supposed future rival, Bayer's yet-to-be-approved Xarelto (rivaroxaban). Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.